MediciNova, Inc., a biopharmaceutical company, engages in the acquisition and development of small molecule therapeutics worldwide. The company's clinical products under development include MN-001 for the treatment of bronchial asthma, which is in Phase III clinical program; MN-221 for the treatment of status asthmaticus, which is in Phase II clinical trial; MN-166 for the treatment of multiple sclerosis that is in a two year randomized, double-blind, placebo-controlled multi-center Phase II clinical trial; and MN-001 for the treatment of interstitial cystitis, which completed a Phase II/III clinical trial. It also develops MN-029 for the treatment of solid tumors, which completed Phase I clinical trial; MN-305 for the treatment of generalized anxiety disorder, which completed a Phase II/III clinical trial; MN-305 for the treatment of insomnia that is in Phase II clinical trial; and MN-221 for the treatment of preterm labor, which is in Phase Ib clinical study. In addition, the company develops MN-246 for the treatment of urinary incontinence, which completed a double-blind, randomized, placebo-controlled, single escalating dose Phase I clinical trial; MN-447 for the treatment of thrombotic disorders, which is in preclinical development stage; and MN-462 for the treatment of thrombotic disorders, which is in preclinical development stage. MediciNova, Inc. has strategic alliances with Kissei Pharmaceutical Co, Ltd.; Kyorin Pharmaceutical; Mitsubishi Pharma Corporation; Meiji Seika Kaisha, Ltd.; and Angiogene Pharmaceuticals, Ltd. The company was founded in 2000 and is headquartered in San Diego, California.